Recombinant human erythropoietin in an Italian cohort of anaemic HIV- infected patients taking zidovudine

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Twenty-one HIV-infected patients were enrolled in an open trial to assess the safety and efficacy of recombinant human erythropoietin (r-HuEPO) in treating zidovudine (AZT)-related anaemia. Eleven patients successfully completed the 6-month study, achieving mean increases of 3.4 g/dL in haemoglobin and of 10.1 percentage points in haematocrit. The only side effect that was possibly related to treatment was transient headache, reported by 2 patients. For the 10 patients who failed to complete the trial, treatment was discontinued in 6 cases due to development of opportunistic infections [Pneumocystis carinii pneumonia (PCP) in 3 cases, neuromeningeal cryptococcosis in 1, Escherichia coli in 1, and neural toxoplasmosis in 1]; 3 failed to respond to treatment (2 with baseline erythropoietin levels <500 U/L and 1 with baseline erythropoietin of more than 2900 U/L); and 1 patient developed a psychosis, for which she had been treated many times since adolescence. In contrast to other studies reported in the literature, the baseline erythropoietin levels of our patients were lower (<100 U/L in 15 cases and <500 U/L in all but one case), and there was no correlation between haemoglobin at enrollment and the baseline erythropoietin level. Nevertheless, this study demonstrates the excellent tolerance of r-HuEPO and its effectiveness in treating HIV/AZT-related anaemia.

Original languageEnglish
Title of host publicationArchives of STD/HIV Research
Pages85-95
Number of pages11
Volume7
Edition2
Publication statusPublished - 1993

Fingerprint

Zidovudine
Erythropoietin
HIV
Anemia
Hemoglobins
Cryptococcosis
Pneumocystis Pneumonia
Toxoplasmosis
Opportunistic Infections
Hematocrit
Psychotic Disorders
Headache
Therapeutics
Escherichia coli
Safety

ASJC Scopus subject areas

  • Dermatology
  • Immunology and Allergy
  • Microbiology (medical)

Cite this

Recombinant human erythropoietin in an Italian cohort of anaemic HIV- infected patients taking zidovudine. / Maserati, R.; Nai, C.; Minoli, L.

Archives of STD/HIV Research. Vol. 7 2. ed. 1993. p. 85-95.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{5209ac4caeda44ed9a94d73bbc7104e8,
title = "Recombinant human erythropoietin in an Italian cohort of anaemic HIV- infected patients taking zidovudine",
abstract = "Twenty-one HIV-infected patients were enrolled in an open trial to assess the safety and efficacy of recombinant human erythropoietin (r-HuEPO) in treating zidovudine (AZT)-related anaemia. Eleven patients successfully completed the 6-month study, achieving mean increases of 3.4 g/dL in haemoglobin and of 10.1 percentage points in haematocrit. The only side effect that was possibly related to treatment was transient headache, reported by 2 patients. For the 10 patients who failed to complete the trial, treatment was discontinued in 6 cases due to development of opportunistic infections [Pneumocystis carinii pneumonia (PCP) in 3 cases, neuromeningeal cryptococcosis in 1, Escherichia coli in 1, and neural toxoplasmosis in 1]; 3 failed to respond to treatment (2 with baseline erythropoietin levels <500 U/L and 1 with baseline erythropoietin of more than 2900 U/L); and 1 patient developed a psychosis, for which she had been treated many times since adolescence. In contrast to other studies reported in the literature, the baseline erythropoietin levels of our patients were lower (<100 U/L in 15 cases and <500 U/L in all but one case), and there was no correlation between haemoglobin at enrollment and the baseline erythropoietin level. Nevertheless, this study demonstrates the excellent tolerance of r-HuEPO and its effectiveness in treating HIV/AZT-related anaemia.",
author = "R. Maserati and C. Nai and L. Minoli",
year = "1993",
language = "English",
volume = "7",
pages = "85--95",
booktitle = "Archives of STD/HIV Research",
edition = "2",

}

TY - CHAP

T1 - Recombinant human erythropoietin in an Italian cohort of anaemic HIV- infected patients taking zidovudine

AU - Maserati, R.

AU - Nai, C.

AU - Minoli, L.

PY - 1993

Y1 - 1993

N2 - Twenty-one HIV-infected patients were enrolled in an open trial to assess the safety and efficacy of recombinant human erythropoietin (r-HuEPO) in treating zidovudine (AZT)-related anaemia. Eleven patients successfully completed the 6-month study, achieving mean increases of 3.4 g/dL in haemoglobin and of 10.1 percentage points in haematocrit. The only side effect that was possibly related to treatment was transient headache, reported by 2 patients. For the 10 patients who failed to complete the trial, treatment was discontinued in 6 cases due to development of opportunistic infections [Pneumocystis carinii pneumonia (PCP) in 3 cases, neuromeningeal cryptococcosis in 1, Escherichia coli in 1, and neural toxoplasmosis in 1]; 3 failed to respond to treatment (2 with baseline erythropoietin levels <500 U/L and 1 with baseline erythropoietin of more than 2900 U/L); and 1 patient developed a psychosis, for which she had been treated many times since adolescence. In contrast to other studies reported in the literature, the baseline erythropoietin levels of our patients were lower (<100 U/L in 15 cases and <500 U/L in all but one case), and there was no correlation between haemoglobin at enrollment and the baseline erythropoietin level. Nevertheless, this study demonstrates the excellent tolerance of r-HuEPO and its effectiveness in treating HIV/AZT-related anaemia.

AB - Twenty-one HIV-infected patients were enrolled in an open trial to assess the safety and efficacy of recombinant human erythropoietin (r-HuEPO) in treating zidovudine (AZT)-related anaemia. Eleven patients successfully completed the 6-month study, achieving mean increases of 3.4 g/dL in haemoglobin and of 10.1 percentage points in haematocrit. The only side effect that was possibly related to treatment was transient headache, reported by 2 patients. For the 10 patients who failed to complete the trial, treatment was discontinued in 6 cases due to development of opportunistic infections [Pneumocystis carinii pneumonia (PCP) in 3 cases, neuromeningeal cryptococcosis in 1, Escherichia coli in 1, and neural toxoplasmosis in 1]; 3 failed to respond to treatment (2 with baseline erythropoietin levels <500 U/L and 1 with baseline erythropoietin of more than 2900 U/L); and 1 patient developed a psychosis, for which she had been treated many times since adolescence. In contrast to other studies reported in the literature, the baseline erythropoietin levels of our patients were lower (<100 U/L in 15 cases and <500 U/L in all but one case), and there was no correlation between haemoglobin at enrollment and the baseline erythropoietin level. Nevertheless, this study demonstrates the excellent tolerance of r-HuEPO and its effectiveness in treating HIV/AZT-related anaemia.

UR - http://www.scopus.com/inward/record.url?scp=0027267152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027267152&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:0027267152

VL - 7

SP - 85

EP - 95

BT - Archives of STD/HIV Research

ER -